Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO – Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $19.78, but opened at $20.54. Zenas BioPharma shares last traded at $20.9480, with a volume of 16,354 shares changing hands.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on the stock. Morgan Stanley lifted their target price on shares of Zenas BioPharma from $21.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Zacks Research raised Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Wall Street Zen upgraded Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Friday, March 27th. Finally, HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $44.29.
Get Our Latest Research Report on ZBIO
Zenas BioPharma Price Performance
Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.01. During the same period in the prior year, the business earned ($0.80) EPS. Research analysts forecast that Zenas BioPharma, Inc. will post -4.47 earnings per share for the current year.
Insider Buying and Selling at Zenas BioPharma
In other Zenas BioPharma news, Director Hongbo Lu purchased 3,768 shares of the firm’s stock in a transaction that occurred on Tuesday, March 31st. The stock was bought at an average cost of $18.63 per share, for a total transaction of $70,197.84. Following the purchase, the director directly owned 426,736 shares in the company, valued at $7,950,091.68. The trade was a 0.89% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Leon O. Moulder, Jr. purchased 60,000 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were acquired at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the completion of the transaction, the chief executive officer owned 96,928 shares in the company, valued at $1,636,144.64. This trade represents a 162.48% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders bought 273,768 shares of company stock valued at $5,150,198. 22.00% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Zenas BioPharma
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of Zenas BioPharma by 25.0% in the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock worth $52,761,000 after purchasing an additional 290,307 shares in the last quarter. NEXTBio Capital Management LP purchased a new stake in shares of Zenas BioPharma in the 4th quarter worth approximately $11,691,000. EcoR1 Capital LLC bought a new position in Zenas BioPharma during the 4th quarter valued at approximately $28,667,000. Polar Capital Holdings Plc bought a new position in Zenas BioPharma during the 4th quarter valued at approximately $38,402,000. Finally, UBS Group AG increased its position in Zenas BioPharma by 95.8% during the 4th quarter. UBS Group AG now owns 69,495 shares of the company’s stock valued at $2,523,000 after buying an additional 34,003 shares in the last quarter.
About Zenas BioPharma
Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.
Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.
Featured Articles
- Five stocks we like better than Zenas BioPharma
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Zenas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
